# InMed Pharmaceuticals Inc.: financial statements, quarterly

INM · Nasdaq · CIK 1728328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/inm.md) · [Financials](/companies/inm/financials.md) · [Filings](/companies/inm/filings.md) · [Insiders](/companies/inm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | period not labelled (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [902](/filings/0001213900-24-098445.md) | [1,240](/filings/0001213900-25-013063.md) | [1,173](/filings/0001213900-25-042126.md) | [1,283 d](/filings/0001213900-25-090210.md) | [1,265](/filings/0001213900-25-107152.md) | [1,112](/filings/0001213900-26-014996.md) | [1,262](/filings/0001213900-25-042126.md) | [1,305 d](/filings/0001213900-25-090210.md) | [1,120](/filings/0001213900-25-107152.md) | [820](/filings/0001213900-26-014996.md) | not reported | not reported |
| Cost of revenue | $k | [881](/filings/0001213900-24-098445.md) | [916](/filings/0001213900-25-013063.md) | [883](/filings/0001213900-25-042126.md) | [817 d](/filings/0001213900-25-090210.md) | [771](/filings/0001213900-25-107152.md) | [651](/filings/0001213900-26-014996.md) | [1,086](/filings/0001213900-25-042126.md) | [728 d](/filings/0001213900-25-090210.md) | [717](/filings/0001213900-25-107152.md) | [636](/filings/0001213900-26-014996.md) | not reported | not reported |
| Gross profit | $k | [21.2](/filings/0001213900-24-098445.md) | [324](/filings/0001213900-25-013063.md) | [289](/filings/0001213900-25-042126.md) | [466 d](/filings/0001213900-25-090210.md) | [493](/filings/0001213900-25-107152.md) | [461](/filings/0001213900-26-014996.md) | [176](/filings/0001213900-25-042126.md) | [577 d](/filings/0001213900-25-090210.md) | [403](/filings/0001213900-25-107152.md) | [184](/filings/0001213900-26-014996.md) | not reported | not reported |
| Research and development | $k | [1,292](/filings/0001213900-24-098445.md) | [610](/filings/0001213900-25-013063.md) | [657](/filings/0001213900-25-042126.md) | [659 d](/filings/0001213900-25-090210.md) | [700](/filings/0001213900-25-107152.md) | [895](/filings/0001213900-26-014996.md) | [425](/filings/0001213900-26-052920.md) | [577 d](/filings/0001213900-26-098419.md) | [582](/filings/0001213900-25-107152.md) | [631](/filings/0001213900-26-014996.md) | [1,023](/filings/0001213900-26-052920.md) | [806 d](/filings/0001213900-26-098419.md) |
| Operating income | $k | [(2,537)](/filings/0001213900-23-086255.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,537)](/filings/0001213900-25-042126.md) | [(1,478)](/filings/0001213900-25-042126.md) | [(1,723)](/filings/0001213900-25-042126.md) | [(1,938) d](/filings/0001213900-25-090210.md) | [(1,678)](/filings/0001213900-26-052920.md) | [(2,575)](/filings/0001213900-26-052920.md) | [(2,121)](/filings/0001213900-26-052920.md) | [(1,788) d](/filings/0001213900-26-098419.md) | [(1,727)](/filings/0001213900-26-052920.md) | [(2,028)](/filings/0001213900-26-052920.md) | [(2,966)](/filings/0001213900-26-052920.md) | [(5,839) d](/filings/0001213900-26-098419.md) |
| Diluted EPS | $ per share | [(15.24)](/filings/0001213900-24-098445.md) | [(3.71)](/filings/0001213900-25-013063.md) | [(3.58)](/filings/0001213900-25-042126.md) | not reported | [(2.71)](/filings/0001213900-25-107152.md) | [(3.64)](/filings/0001213900-26-014996.md) | [(1.94)](/filings/0001213900-26-052920.md) | not reported | [(0.44)](/filings/0001213900-25-107152.md) | [(0.51)](/filings/0001213900-26-014996.md) | [(0.73)](/filings/0001213900-26-052920.md) | not reported |
| Basic EPS | $ per share | [(15.24)](/filings/0001213900-24-098445.md) | [(3.71)](/filings/0001213900-25-013063.md) | [(3.58)](/filings/0001213900-25-042126.md) | not reported | [(2.71)](/filings/0001213900-25-107152.md) | [(3.64)](/filings/0001213900-26-014996.md) | [(1.94)](/filings/0001213900-26-052920.md) | not reported | [(0.44)](/filings/0001213900-25-107152.md) | [(0.51)](/filings/0001213900-26-014996.md) | [(0.73)](/filings/0001213900-26-052920.md) | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | period not labelled (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.7](/filings/0001213900-24-098445.md) | [9.5](/filings/0001213900-24-013414.md) | not reported | [6.6](/filings/0001213900-25-090210.md) | [5.6](/filings/0001213900-24-098445.md) | [3.4](/filings/0001213900-25-013063.md) | [4.7](/filings/0001213900-25-042126.md) | [10.7](/filings/0001213900-26-052920.md) | [9.3](/filings/0001213900-25-107152.md) | [7.0](/filings/0001213900-26-014996.md) | [5.2](/filings/0001213900-26-052920.md) | not reported |
| Current assets | $m | [8.3](/filings/0001213900-23-086255.md) | [11.8](/filings/0001213900-24-013414.md) | not reported | [8.7](/filings/0001213900-25-090210.md) | [7.3](/filings/0001213900-24-098445.md) | [5.5](/filings/0001213900-25-013063.md) | [6.4](/filings/0001213900-25-042126.md) | [12.9](/filings/0001213900-26-098419.md) | [10.8](/filings/0001213900-25-107152.md) | [8.8](/filings/0001213900-26-014996.md) | [6.9](/filings/0001213900-26-052920.md) | [2.7](/filings/0001213900-26-098419.md) |
| Total assets | $m | [10.9](/filings/0001213900-23-086255.md) | [15.3](/filings/0001213900-24-013414.md) | not reported | [11.8](/filings/0001213900-25-090210.md) | [10.5](/filings/0001213900-24-098445.md) | [8.5](/filings/0001213900-25-013063.md) | [9.3](/filings/0001213900-25-042126.md) | [15.6](/filings/0001213900-26-098419.md) | [13.4](/filings/0001213900-25-107152.md) | [11.2](/filings/0001213900-26-014996.md) | [9.1](/filings/0001213900-26-052920.md) | [3.0](/filings/0001213900-26-098419.md) |
| Current liabilities | $m | [1.3](/filings/0001213900-23-086255.md) | [1.7](/filings/0001213900-24-013414.md) | not reported | [2.0](/filings/0001213900-25-090210.md) | [1.4](/filings/0001213900-24-098445.md) | [1.8](/filings/0001213900-25-013063.md) | [1.8](/filings/0001213900-25-042126.md) | [1.8](/filings/0001213900-26-098419.md) | [1.6](/filings/0001213900-25-107152.md) | [1.5](/filings/0001213900-26-014996.md) | [2.2](/filings/0001213900-26-052920.md) | [2.0](/filings/0001213900-26-098419.md) |
| Total liabilities | $m | [1.3](/filings/0001213900-23-086255.md) | [2.5](/filings/0001213900-24-013414.md) | not reported | [2.6](/filings/0001213900-25-090210.md) | [2.1](/filings/0001213900-24-098445.md) | [2.3](/filings/0001213900-25-013063.md) | [2.3](/filings/0001213900-25-042126.md) | [2.1](/filings/0001213900-26-098419.md) | [1.8](/filings/0001213900-25-107152.md) | [1.6](/filings/0001213900-26-014996.md) | [2.2](/filings/0001213900-26-052920.md) | [2.0](/filings/0001213900-26-098419.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(9.6)](/filings/0001213900-25-042126.md) | [12.8](/filings/0001213900-25-042126.md) | [11.1](/filings/0001213900-25-042126.md) | [9.2](/filings/0001213900-26-098419.md) | [8.4](/filings/0001213900-26-052920.md) | [6.2](/filings/0001213900-26-052920.md) | [7.0](/filings/0001213900-26-052920.md) | [13.4](/filings/0001213900-26-098419.md) | [11.6](/filings/0001213900-26-052920.md) | [9.6](/filings/0001213900-26-052920.md) | [6.9](/filings/0001213900-26-052920.md) | [1.1](/filings/0001213900-26-098419.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | period not labelled (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,174)](/filings/0001213900-24-098445.md) | [(1,848) d](/filings/0001213900-25-013063.md) | [(1,934) d](/filings/0001213900-25-042126.md) | [(1,029) d](/filings/0001213900-25-090210.md) | [(1,827)](/filings/0001213900-25-107152.md) | [(2,502) d](/filings/0001213900-26-014996.md) | [(1,659) d](/filings/0001213900-26-052920.md) | [(2,111) d](/filings/0001213900-26-098419.md) | [(1,608)](/filings/0001213900-25-107152.md) | [(2,376) d](/filings/0001213900-26-014996.md) | [(1,695) d](/filings/0001213900-26-052920.md) | [(2,965) d](/filings/0001213900-26-098419.md) |
| Capital expenditure | $k | not reported | not reported | [0.0 d](/filings/0001213900-25-042126.md) | [0.0 d](/filings/0001213900-25-090210.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | period not labelled (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [866](/filings/0001213900-23-086255.md) | [2,301](/filings/0001213900-24-013414.md) | [3,328](/filings/0001213900-23-039477.md) | [166](/filings/0001213900-24-098445.md) | [399](/filings/0001213900-25-013063.md) | [481](/filings/0001213900-25-042126.md) | [620](/filings/0001213900-25-107152.md) | [707](/filings/0001213900-26-014996.md) | [1,096](/filings/0001213900-26-052920.md) | [3,955](/filings/0001213900-25-107152.md) | [3,955](/filings/0001213900-26-014996.md) | [4,048](/filings/0001213900-26-052920.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,493,735 at 2026-09-02, from the cover of the [10-K filed 2026-09-09](/filings/0001213900-26-098419.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.